MMP-13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation
By: Svenja Meierjohann , Anita Hufnagel , Elisabeth Wende , Markus A Kleinschmidt , Katarina Wolf , Peter Friedl , Stefan Gaubatz and Manfred Schartl

Molecular Cancer 2010, 9:201 doi:10.1186/1476-4598-9-201
Published: 28 July 2010

Abstract (Provisional)

Background

Melanoma cells are usually characterized by a strong proliferative potential and efficient invasive migration. Among the multiple molecular changes that are recorded during progression of this disease, aberrant activation of receptor tyrosine kinases (RTK) is often observed. Activation of matrix metalloproteases goes along with RTK activation and usually enhances RTK-driven migration. The purpose of this study was to examine RTK-driven three-dimensional migration of melanocytes and the pro-tumorigenic role of matrix metalloproteases for melanocytes and melanoma cells.

Results

Using experimental melanocyte dedifferentiation as a model for early melanomagenesis we show that an activated EGF receptor variant potentiates migration through three-dimensional fibrillar collagen. EGFR stimulation also resulted in a strong induction of matrix metalloproteases in a MAPK-dependent manner. However, neither MAPK nor MMP activity were required for migration, as the cells migrated in an entirely amoeboid mode. Instead, MMPs fulfilled a function in cell cycle regulation, as their inhibition resulted in strong growth inhibition of melanocytes. The same effect was observed in human melanoma cells that were stimulated with FCS. Using sh- and siRNA techniques, we could show that MMP13 is the single protease responsible for this effect. Along with decreased proliferation, knockdown of MMP13 strongly enhanced pigmentation of melanocytes.

Conclusions

Our data show for the first time that growth stimuli are mediated via MMP13 in melanocytes and melanoma, suggesting an autocrine MMP13-driven loop. Given that MMP13-specific inhibitors are already developed, our results support the evaluation of these inhibitors in the treatment of melanoma.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements